Elicio Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Elicio Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
Elicio Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 253 %.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	253	+267		Jun 30, 2024
Q1 2024	126	+136		Mar 31, 2024
Q4 2023	-80.5	-66.9	-493%	Dec 31, 2023
Q3 2023	-27.2	-12.1	-80.6%	Sep 30, 2023
Q2 2023	-14.4	+33.1	+69.6%	Jun 30, 2023
Q1 2023	-9.59	+850	+98.9%	Mar 31, 2023
Q4 2022	-13.6	-111	-114%	Dec 31, 2022
Q3 2022	-15.1	-209	-108%	Sep 30, 2022
Q2 2022	-47.5			Jun 30, 2022
Q1 2022	-860			Mar 31, 2022
Q4 2021	97.3			Dec 31, 2021
Q3 2021	194			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.